Merck Research Laboratories CMO Roy Baynes

Mer­ck­'s Keytru­da un­corks full da­ta on lat­est ad­ju­vant win — this time in melanoma — adding bricks to ear­ly can­cer wall

In re­cent months, the bat­tle for PD-(L)1 dom­i­nance has spilled over in­to ear­ly can­cer with Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo all alone on the front lines. Keytru­da now has an­oth­er shell in its ban­dolier, and it could spell a quick ap­proval.

Keytru­da cut the risk of re­lapse or death by 35% over place­bo (p=0.00658) in high-risk, stage 2 melanoma pa­tients who had pre­vi­ous­ly un­der­gone surgery to re­move their tu­mors, ac­cord­ing to full da­ta from the Phase III KEYNOTE-716 pre­sent­ed Sat­ur­day at #ES­MO21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.